Natural History Study of BAG3 Heart Disease in Chinese Adults
Part of Genetic & congenital, Heart & circulation clinical trials.
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with a BAG3 gene mutation (confirmed by genetic testing)
- You have heart failure that is Stage B or C, with mild to moderate symptoms (NYHA Class I–III)
- Your heart's pumping ability is reduced (LVEF of 50% or lower, confirmed by heart ultrasound or MRI within the past year)
- You are able and willing to attend all study visits and follow all study procedures
- You have not had a major heart event or surgery in the past 1–3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic mutation (R14del in the PLN gene). The goal is to see if the drug can improve heart function and symptoms.
This study looks at people with cardiomyopathy (or related heart muscle conditions) and those who may be at risk because of family history or genetic test results. It may help researchers better understand who is likely to develop the condition and how best to monitor or support them.
This study follows people with a specific genetic change (in the BAG3 gene) that causes heart muscle weakness, to learn more about how the condition progresses over time. It does not test a new drug, but it helps researchers understand the disease better, which may lead to future treatments.
This trial tests an experimental gene therapy (AFTX-201) designed to address the genetic cause of heart failure in people with a specific BAG3 gene mutation. It aims to improve heart function and reduce symptoms.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.